Elevated Plasma Immunoreactive Neuropeptide Y Concentrations and Its Increased Urinary Excretion in Patients with Advanced Diabetic Nephropathy.
|
Accession number;99A0439790
|
| Title;Elevated Plasma Immunoreactive Neuropeptide Y Concentrations and Its Increased Urinary Excretion in Patients with Advanced Diabetic Nephropathy. |
| Author;
SATOH C
(Tohoku Univ. School Of Medicine, Miyagi, Jpn)
SATOH F
(Tohoku Univ. School Of Medicine, Miyagi, Jpn)
TAKAHASHI K
(Tohoku Univ. School Of Medicine, Miyagi, Jpn)
MURAKAMI O
(Tohoku Univ. School Of Medicine, Miyagi, Jpn)
SONE M
(National Iwate Hospital, Iwate, Jpn)
YABE T
(Iwadeyama Hospital, Miyagi, Jpn)
NAGAKUBO H
(Tohoku Univ. School Of Medicine, Miyagi, Jpn)
SATO T
(Tohoku Univ. School Of Medicine, Miyagi, Jpn)
MOURI T
(Mouri Clinic, Miyagi, Jpn)
|
Journal Title;Endocr J
|
Journal Code:F0625A
|
ISSN:0918-8959
|
|
VOL.46;NO.1;PAGE.139-146(1999)
|
| Figure&Table&Reference;FIG.3, TBL.2, REF.38 |
| Pub. Country;Japan |
| Language;English |
| Abstract;Neuropeptide Y(NPY) is a potent vasoconstrictor peptide that is abundant in the brain and the peripheral sympathetic nervous system. In the present study we investigated possible changes in plasma immunoreactive(IR)-NPY concentrations and urinary IR-NPY excretion in patients with non-insulin dependent diabetes mellitus(NIDDM) and the relationship to diabetic complications, such as nephropathy and neuropathy. IR-NPY in plasma and urine was measured by radioimmunoassay in 69 patients with NIDDM. Plasma IR-NPY concentrations in patients with advanced nephropathy(creatinine clearance<30ml/min)(100.5.+-.10.3pmol/l, n=9, mean.+-.SEM) were higher than in the control subjects(55.0.+-.6.8pmol/l, n=15)(P<0.02). Urinary excretion of IR-NPY and fractional excretion of NPY were also increased in the patients with advanced nephropathy. Sephadex G-50 column chromatography of the urine extracts obtained from healthy subjects, diabetic patients with renal failure and non-diabetic patients with renal failure showed an immunoreactive peak eluting in the NPY position. On the other hand, neither plasma nor urinary IR-NPY was high in patients with retinopathy, or in patients with peripheral neuropathy. The present study has, for the first time, shown high plasma IR-NPY concentrations and urinary IR-NPY excretion in NIDDM patients with advanced nephropathy. (author abst.) |
|
|
|
Related Articles;
|
|
|
